Francisco J. Esteva: KEYNOTE-522 Trial Shows Pembrolizumab Boosts Survival in Triple-Negative Breast Cancer

Francisco J. Esteva, Chief, Division of Hematology and Medical Oncology at Lenox Hill Hospital, posted the following on LinkedIn:

“The KEYNOTE-522 trial shows that adding pembrolizumab to the standard neoadjuvant chemotherapy significantly boosts outcomes for early-stage triple-negative breast cancer patients. The study previously found higher pathological complete response rates, along with better event-free survival.

A recent update showed a significant improvement in overall survival rate, compared to just chemotherapy, cutting the risk of death by more than 34%.

This is great news for patients with high-risk early-stage triple-negative breast cancer, confirming immunotherapy is a major advance in breast cancer therapy.”

Source: Francisco J. Esteva/LinkedIn